Veradermics, Incorporated (MANE), a late clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 15.08 million shares at $17 per share.
In addition, Veradermics has granted the underwriters a 30-day option to purchase up to an additional 2.26 million shares.
Gross proceeds from the offering, which is expected to close on February 5, are estimated to be approximately $256.3 million.
Veradermics' stock is expected to begin trading on the New York Stock Exchange on February 4, under the ticker symbol MANE.
Jefferies, Leerink Partners, Citigroup, and Cantor are acting as joint book-running managers for the offering.
For comments and feedback contact: editorial@rttnews.com
Business News
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.